White label ELPA - ClinicalTrials.eu

Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

Not recruiting

2 1
Investigated Diseases:
- Colitis ulcerative
Investigated Drugs:
- Rifamycin Sodium
+1
Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Not recruiting

3 1 1
Investigated Drugs:
- Niraparib Tosilate Monohydrate
- Pembrolizumab
+8
Study on the Effectiveness of Thyme Herb Extract, Primrose Root Tincture, and Ivy Leaf Extract for Patients with Acute Bronchitis

Not recruiting

3 1 1 1
Investigated Diseases:
- Bronchitis
Investigated Drugs:
Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated Drugs:
- Alectinib
- Durvalumab
+3
Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Not recruiting

2 1 1 1
Investigated Diseases:
- Plasma cell myeloma
Investigated Drugs:
Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
+3
Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

Not recruiting

3 1 1
Investigated Diseases:
- Type 2 diabetes mellitus
Investigated Drugs:
- Semaglutide
+4
Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

Not recruiting

1 1 1 1
Investigated Drugs:
Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Not recruiting

3 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Not recruiting

3 1 1 1
Investigated Drugs:
- Luspatercept
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies